文献速递鼻科

真实世界中度普利尤单抗与奥马珠单抗治疗慢性鼻窦炎:韩国国民健康保险服务数据库结果

Real-world treatment of chronic rhinosinusitis with dupilumab and omalizumab: results from the Korean National Health Insurance Service database.
PubMed 文献 · Rhinology · 2025-01-01

本研究基于韩国国民健康保险服务数据库(2010年1月至2024年3月),分析808例接受度普利尤单抗或奥马珠单抗治疗的慢性鼻窦炎伴鼻息肉患者的实际给药模式及全身糖皮质激素使用情况。结果显示,治疗12周时46.2%的患者接受度普利尤单抗2周间隔给药,53.9%的奥马珠单抗患者接受2周或4周间隔给药;生物制剂治疗患者年费用高于其他治疗,全身激素年均使用天数从33.0天降至12.7天。作者认为真实世界给药与推荐剂量存在差异,需进一步研究可行的给药方案。

要点

  • 治疗12周时46.2%的患者接受度普利尤单抗2周间隔给药,53.9%的奥马珠单抗患者接受2周或4周间隔给药。
  • 生物制剂治疗患者年费用高于接受其他治疗的慢性鼻窦炎患者。
  • 使用生物制剂后全身激素年均使用天数从33.0天降至12.7天。

核心结论

  • 基于大样本真实世界数据的分析提示,生物制剂的推荐剂量与实际给药模式之间存在差异。
  • 作者认为需要进一步研究可行的给药方案,以反映多种患者因素和医疗费用。

研究设计与样本

  • 基于韩国国民健康保险服务(NHIS)数据库的分析,数据时间段为2010年1月至2024年3月。
  • 纳入经ICD-10编码定义、接受过计算机断层扫描且有度普利尤单抗或奥马珠单抗处方史的慢性鼻窦炎或鼻息肉患者,共分析808例患者的给药模式和全身糖皮质激素使用情况。

主要发现

  • 治疗开始12周后,46.2%的患者接受度普利尤单抗2周间隔给药。
  • 治疗开始12周后,53.9%的奥马珠单抗患者接受2周或4周间隔给药。
  • 接受生物制剂治疗的慢性鼻窦炎患者年费用高于接受其他治疗的患者。
  • 使用生物制剂后,全身激素年均使用天数从33.0天降至12.7天。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 作者认为需要进一步研究可行的给药方案,以反映多种患者因素和医疗费用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Biological treatment has proven effective for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP) and is increasingly prescribed. However, in the real-world, strict adherence to the recommended dose may not be feasible and studies on the actual administration patterns of biologics are limited. This study aimed to evaluate the patterns of real-world use of biologics for CRS in Korea, through the National Health Insurance Service (NHIS). METHODS: We analysed data from the NHIS database from January 2010 to March 2024. Patients with CRS or nasal polyp defined by the ICD-10 codes, who had undergone computed tomography, and had a history of being prescribed dupilumab or omalizumab were identified. A total of 808 patients were analysed for their administration patterns and systemic corticosteroid use. RESULTS: Twelve weeks after initiation of therapy, 46.2% of patients received dupilumab at 2-weekly intervals and 53.9% of patients on omalizumab patients were receiving treatment at 2- or 4-week intervals. The annual expense of CRS patients treated with biologics was greater than for those receiving other treatments. The average annual usage of systemic steroids was decreased from 33.0 days to 12.7 days after using biologics. CONCLUSIONS: The results of this study which analysed real-world data in a large population, suggest a discrepancy between the recommended dose and real-world administration of biologics. Further studies are warranted on feasible administration schedules that reflect various patient factors and healthcare costs.

来源:Rhinology,查看原文。版权归原作者所有。

引用

  1. Han SA, Yoon J, Kim BH, et al. Real-world treatment of chronic rhinosinusitis with dupilumab and omalizumab: results from the Korean National Health Insurance Service database. Rhinology. 2025. PMID: 39968898. doi:10.4193/Rhin24.209

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。